Abstract

This study aimed to investigate parameters for medication-related osteonecrosis of jaw (MRONJ) patients using the bone SPECT/CT, especially bone mineral-based parameters. Sixty-three patients with MRONJ (43 osteoporosis and 20 bone metastasises) underwent CT, MRI and SPECT/CT. A commercially available software automatically detected lesion area and calculated the quantitative SPECT/CT parameters as bone mineral-based standardized uptake value (SUV). Regarding stage of MRONJ patients, bone mineral based maximum SUV of stage 3 was significantly higher than stage 1, 2 (P = 0.018). Regarding duration of medication therapy, bone mineral based maximum SUV 1 year or more was significantly higher than less than 1 year P = 0.019). Regarding present of periosteal bone proliferation on CT, bone mineral based maximum SUV was significantly higher than those of absent (P = 0.029). Regarding spread of soft tissue inflammation on MRI, bone mineral based maximum SUV of 2 or more was significantly higher than those of less than 2 spaces (P = 0.025). Regarding blood pool phase imaging with SPECT, bone mineral based maximum SUV of intense uptake was significantly higher than those of decrease uptake (P = 0.002). SPECT/CT bone mineral-based parameters indicated significant difference in staging, dosing period, periosteal bone proliferation on CT, spread of soft tissue inflammation on MRI, and blood phase imaging with SPECT. Bone SPECT/CT bone mineral-based parameters are helpful for the assessment of MRONJ.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.